Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Sustainable remission between 52 and 78 weeks: complete or partial remission (primary outcome 1, 2, 3) · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Complete remission: all renal pathologies · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete remission: all renal pathologies compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete remission: FSGS compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete or partial remission compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete or partial remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete or partial remission: FSGS compared with prednisone or placebo (low certainty).
1 finding from 1 review
Treatment failure · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in treatment failure compared with prednisone or placebo (low certainty).
1 finding from 1 review
Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
1 finding from 1 review
Adverse events: hypertension with seizures · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
1 finding from 1 review
Complete remission (no further aphthous episodes to 6 months) · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 6 months: partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete or partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ Sustained remission/steroid sensitive relapses Clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: sustained… compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ CKD clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: CKD compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review